Bausch + Lomb Seeks FDA Approval for Compound to Treat Inflammation Following Cataract Surgery

Bausch + Lomb has announced it submitted a new drug application to FDA seeking approval for a once-daily topical nonsteroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery, according to a news release.

 

The compound, named PROLENSA, was developed by recently acquired ISTA Pharmaceuticals.

 

"The PROLENSA filing is an important step towards bringing safe, effective and meaningful medical advances to medical professionals and their patients," said Marvin Garrett, vice president of U.S. regulatory affairs, quality assurance and compliance for Bausch + Lomb, in the release. "It's also a timely example of the progress we continue to make on critical D&R programs as we work to bring together the best of ISTA Pharmaceuticals and Bausch + Lomb."

 

Related Articles on FDA Clearances:

Medtronic Receives Expanded FDA Clearance for Pillar Palatal Implant System

St. Jude Receives FDA Clearance for Ultrasound Catheter

Kimberly-Clark Health Care Receives FDA Clearance for Sterilization Wrap Portfolio

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast